Syndecan-4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes

Adv Healthc Mater. 2016 May;5(9):1008-13. doi: 10.1002/adhm.201500993. Epub 2016 Feb 18.

Abstract

Delivering syndecan-4 with FGF-2 improves the effectiveness of FGF-2 therapy for ischemia in the diabetic disease state. The syndecan-4 proteoliposomes significantly enhance in vitro tubule formation as well as blood perfusion and vessel density in the ischemic hind limbs of diseased ob/ob mice. Syndecan-4 therapy also induces a marked immunomodulation in the tissues, increasing the polarization of macrophages toward the M2 phenotype.

Keywords: fibroblast growth factor-2 (FGF-2); ischemia; peripheral vascular diseases; syndecan-4; therapeutic angiogenesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / metabolism
  • Diabetes Mellitus, Experimental / pathology
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / pathology
  • Hindlimb / blood supply*
  • Hindlimb / metabolism
  • Hindlimb / pathology
  • Ischemia / drug therapy*
  • Ischemia / metabolism
  • Ischemia / pathology
  • Liposomes
  • Macrophages / metabolism
  • Macrophages / pathology
  • Mice
  • Mice, Obese
  • Neovascularization, Physiologic / drug effects*
  • Syndecan-4 / pharmacology*

Substances

  • Liposomes
  • Sdc4 protein, mouse
  • Syndecan-4